MEDVET SCIENCE LICENSES XL-99 CELL LINE FOR ONCOLOGY ANTIBODY

15 Feb 2015

Medvet Science Pty Ltd has licenced XL-99, a cell line of ACYTE Biotech Pty Ltd, for the clinical development of Medvet’s monoclonal antibody (APOMAB®), intended for the diagnosis and treatment of cancers. Please see press release here. For further information please contact Dr Aoife Cullen, aoife@acyte.com.au.

Back to news

News